DK2388315T3 - Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling - Google Patents

Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Info

Publication number
DK2388315T3
DK2388315T3 DK11174887.7T DK11174887T DK2388315T3 DK 2388315 T3 DK2388315 T3 DK 2388315T3 DK 11174887 T DK11174887 T DK 11174887T DK 2388315 T3 DK2388315 T3 DK 2388315T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
myxoma virus
express functional
express
functional
Prior art date
Application number
DK11174887.7T
Other languages
Danish (da)
English (en)
Inventor
John Barrett
Marianne Stanford
Grant Mcfadden
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Application granted granted Critical
Publication of DK2388315T3 publication Critical patent/DK2388315T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK11174887.7T 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling DK2388315T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
EP06705269A EP1863906A4 (en) 2005-03-07 2006-03-06 COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN USED IN THERAPEUTIC TREATMENT

Publications (1)

Publication Number Publication Date
DK2388315T3 true DK2388315T3 (da) 2014-08-25

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11174887.7T DK2388315T3 (da) 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Country Status (14)

Country Link
US (5) US20090035276A1 (enExample)
EP (2) EP1863906A4 (enExample)
JP (2) JP2008531739A (enExample)
KR (1) KR101479093B1 (enExample)
CN (2) CN101137748B (enExample)
AU (1) AU2006222500B2 (enExample)
CA (1) CA2600675C (enExample)
DK (1) DK2388315T3 (enExample)
IL (2) IL185376A0 (enExample)
MX (1) MX2007010962A (enExample)
NZ (2) NZ560840A (enExample)
RU (1) RU2461630C2 (enExample)
UA (1) UA96412C2 (enExample)
WO (1) WO2006094385A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560840A (en) 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
KR20090014364A (ko) 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
DK2717887T3 (en) 2011-06-09 2018-04-09 Univ Florida Methods for treating or preventing graft-versus-host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
SG11202101291VA (en) * 2018-08-08 2021-03-30 Univ Arizona State Method for improved poxvirus yields
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2021046048A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
AU2020361625A1 (en) * 2019-10-10 2022-05-05 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
CA2378567A1 (en) * 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CN1754002B (zh) * 2002-08-12 2010-09-08 杰能斯有限公司 涉及痘病毒和癌的组合物及制备方法
EP1601376B1 (en) * 2003-03-07 2012-05-30 Robarts Research Institute Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
PT1615640E (pt) * 2003-04-22 2007-04-30 Wyeth Corp Combinações antineoplásticas
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2562904C (en) * 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
NZ560840A (en) 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Also Published As

Publication number Publication date
EP2388315A3 (en) 2012-05-02
JP2008531739A (ja) 2008-08-14
EP1863906A1 (en) 2007-12-12
RU2461630C2 (ru) 2012-09-20
EP1863906A4 (en) 2009-06-03
EP2388315B1 (en) 2014-05-21
US20140134134A1 (en) 2014-05-15
AU2006222500B2 (en) 2011-09-01
JP2012236860A (ja) 2012-12-06
RU2007137008A (ru) 2009-04-20
CA2600675C (en) 2015-12-15
WO2006094385A1 (en) 2006-09-14
CN102357104A (zh) 2012-02-22
EP2388315A2 (en) 2011-11-23
IL208070A0 (en) 2010-12-30
IL185376A0 (en) 2008-02-09
JP5674210B2 (ja) 2015-02-25
HK1163175A1 (en) 2012-09-07
CN101137748B (zh) 2011-12-14
KR101479093B1 (ko) 2015-01-26
KR20070110423A (ko) 2007-11-16
IL208070A (en) 2015-06-30
CA2600675A1 (en) 2006-09-14
US20130171106A1 (en) 2013-07-04
US20090035276A1 (en) 2009-02-05
CN101137748A (zh) 2008-03-05
NZ577283A (en) 2010-11-26
CN102357104B (zh) 2016-01-27
AU2006222500A1 (en) 2006-09-14
US9987315B2 (en) 2018-06-05
UA96412C2 (ru) 2011-11-10
US20180256656A1 (en) 2018-09-13
US20110195050A1 (en) 2011-08-11
MX2007010962A (es) 2008-03-10
NZ560840A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
DK2311464T3 (da) Midler til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK2187878T3 (da) Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
CR10508A (es) Nuevo determinante de virulencia dentro de la glicoproteina estructural e2 del virus de la peste porcina clasica
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
DK1907037T3 (da) Medikamentdispenser.
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
DK1833532T3 (da) Sikkerhedssprøjte
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
NL1029015A1 (nl) Therapeutische verbindingen.
BRPI0815773A2 (pt) composto, e, medicamento.
DK2148670T3 (da) Titrering af tapentadol
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0808246A2 (pt) "fralda descartável".
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
BRPI0819992A2 (pt) Métodos para operar um dispositivo médico e para habilitar numerosos aspectos operacionais de um dispositivo médico, e, dispositivo médico
DK2388315T3 (da) Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate